

Special Issue

New Vaccine Technologies and Approaches 2.0

Message from the Guest Editors

The urgent global need for vaccines to prevent COVID-19, allied with the rapid development of immunization approaches targeting SARS-CoV-2, evidences how the vaccinology field has substantially evolved lately. New technologies for antigen design, the rapid discovery of high neutralizing monoclonal antibodies and the development of new delivery platforms are only a few examples. In addition, in recent years, innumerable changes have occurred in terms of density, age and traveling habits of the world population. Thus, changes in vaccine development that can address all these issues need to be implemented. This Special Issue aims to gather the latest research on new vaccine technologies and approaches, including, but not limited to, the following topics:

- Adjuvants;
- Antigen design;
- Delivery platforms;
- Nanoparticle viral vectors;
- Vaccine development for outbreaks;
- Immunization with whole organisms;
- DNA vaccines;
- RNA vaccines;
- Genetic adjuvants.

We look forward to your contribution to this Special Issue!

Guest Editors

Dr. Stephen A. Morris

The Future Vaccine Manufacturing Research Hub, Department of Biochemical Engineering, University College London, Bernard Katz Building, London WC1E 6BT, UK

Dr. Camila Coelho

Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH-Bethesda, MD, USA

Deadline for manuscript submissions

closed (15 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/61376

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).